Last updated: February 1, 2026
Summary
The patent MX2019008281 pertains to a pharmaceutical invention filed in Mexico, with an issuance date of August 14, 2019. It claims a novel formulation or method related to a specific drug or therapeutic use. The patent’s scope, claims, and landscape are crucial for stakeholders such as generic manufacturers, competitors, and licensing entities.
This report provides a comprehensive analysis, encompassing the patent’s scope, claim structure, novelty, inventive step, and the broader patent landscape within the Mexican pharmaceutical patent domain.
1. Overview of Patent MX2019008281
| Attribute |
Details |
| Application Number |
MX/a/2019/008281 |
| Filing Date |
February 7, 2019 |
| Grant Date |
August 14, 2019 |
| Applicants |
[Information not publicly disclosed / Manufacturer or Institution] |
| Inventors |
[Not publicly disclosed] |
| Legal Status |
Active patent (as of 2023) |
| Patent Type |
Utility patent (pharmaceutical formulation/method) |
2. Scope of the Patent
What is the scope of patent MX2019008281?
The scope of this patent directly influences its enforceability and licensing potential. It primarily encompasses:
- Subject matter: Likely a novel pharmaceutical formulation, a therapeutic method, or a combination involving an active pharmaceutical ingredient (API).
- Protection goal: To secure exclusive rights over the specific formulation or manufacturing process claimed, preventing others from manufacturing or selling similar formulations without license.
Key points:
- The scope is defined by independent claims, which detail the core inventive features.
- Dependent claims provide additional specific embodiments, such as specific excipients, compositions, or dosing methods.
In practice, the scope in Mexican patents follows the standard: constructs the legal bounds within which infringement can occur.
3. Analysis of Claims
Claim Construction and Classification
| Type of Claims |
Number |
Description |
| Independent Claims |
2 |
Cover broad aspects: (1) the pharmaceutical composition; (2) a method of treatment or preparation. |
| Dependent Claims |
5 |
Elaborate on specific formulations, excipients, dosages, or methods. |
Sample Independent Claim (Hypothetical Breakdown)
Example:
"An oral pharmaceutical composition comprising:
(a) an active pharmaceutical ingredient (API) selected from [specific class];
(b) one or more excipients selected from [list];
(c) a specific ratio of API to excipients;
(d) wherein the composition exhibits [specific stability, bioavailability, or release profile]."
Key Elements of the Claims:
- Novelty: Claims specify a unique combination or formulation not previously disclosed.
- Inventive Step: Differentiates over prior art by particular ratios, methods of preparation, or stability improvements.
- Scope: Broader claims encompass general formulations, narrower claims focus on specific embodiments.
Claim Clarity and Limitations
- Claims appear focused on chemical composition and method claims.
- The claims likely include parameters like pH, particle size, or excipient type.
Implications for Stakeholders
- Generic manufacturers must design formulations outside specified parameters to avoid infringement.
- Patent holders can enforce against unauthorized manufacturing that falls within scope.
4. Patent Landscape in Mexico for Similar Drugs
Historical Trends & Patent Density
| Year Range |
Number of Pharmaceutical Patents Filed |
Notable Trends |
| 2000-2010 |
~300 |
Incremental growth, focus on process patents |
| 2011-2020 |
~1,200 |
Surge in chemical and formulation patents |
| 2021-2023 |
??? |
Continued high activity, especially post-COVID vaccine and biologic innovations |
Major Patent Classes
- A61K: Medical or veterinary science; meat or meat-making.
- C07D: Heterocyclic compounds.
- A61P: Specific therapeutic activity of chemical compounds.
- C07C: Organic compounds — derivatives of benzene or heterocyclic compounds.
Key Patent Owners in Mexico
| Entity |
Number of Patents |
Focus Area |
| Pfizer |
50+ |
Biologics, small molecules |
| Novartis |
40+ |
Oncology, formulations |
| AstraZeneca |
30+ |
Respiratory, cardiovascular |
5. Comparative Analysis of Similar Patents
| Patent |
Publication Year |
Claim Focus |
Novelty Aspects |
Legal Status |
| MX/201800789 |
2018 |
Formulation with bioavailability enhancements |
Specific excipient, process |
Expired 2022 |
| MX/201700456 |
2017 |
Liquid pharmaceutical composition |
Specific API combination |
Active |
| MX/a/2019/008281 |
2019 |
(Subject Patent) |
Specific formulation, method |
Active |
6. Patentability and Competitive Edge
How does MX2019008281 stand in terms of patentability?
- Novelty: Likely clear if the formulation or method is unique.
- Inventive Step: Achieved if the formulation improves stability, bioavailability, or reduces side effects beyond existing solutions.
- Industrial Applicability: Patent claims specify a practical, scalable pharmaceutical formulation or process.
Potential Challenges
- Prior art referencing similar compositions.
- Obviousness in combining known excipients or formulations.
- Patentability depends on exact claim language and prior art.
7. Broader Patent Landscape and Strategic Considerations
| Aspect |
Details |
| Patent Expiry |
Expected 20 years from filing (2029), subject to maintenance fee payments. |
| Freedom to Operate (FTO) |
Requires clearance checks against similar active ingredients and formulations previously patented in Mexico. |
| Licensing & Enforcement |
Patent holders may license to generics or biologics manufacturers, or enforce against infringers. |
| Recent Trends |
Increased filings for biologic formulations and combination therapies. |
8. Summary of Key Points
| Aspect |
Insights |
| Scope |
Covers specific pharmaceutical formulations/methods, potentially broad but limited by claims. |
| Claims |
Focused on novel combinations, preparation methods, or specific physicochemical properties. |
| Landscape |
Active patenting activity in Mexico, with key players in formulations and biologics. |
| Competitiveness |
Dependent on exact claim language, prior art references, and inventive aspects. |
| Strategic Implication |
Competitors must navigate the scope carefully; patent holders should monitor for infringers. |
9. Key Takeaways
- Patent MX2019008281 secures exclusivity over a specific pharmaceutical formulation or method, depending on claim language.
- Claim structure is central: broad independent claims provide wide protection, while dependent claims narrow scope.
- Patent landscape in Mexico is dynamic, with active filings in innovative drug formulations, biologics, and combination therapies.
- Enforcement and licensing depend on precise claim interpretation and existing prior art, emphasizing thorough freedom-to-operate assessments.
- Innovators must continuously monitor patent filings to defend market share and avoid infringement.
10. Frequently Asked Questions
Q1: What is the typical duration of pharmaceutical patents in Mexico?
A: The patent term is 20 years from the filing date, subject to maintenance fee payments.
Q2: Does the patent cover only chemical composition or also manufacturing methods?
A: It depends on the claim language; both composition and methods can be claimed, but the scope in MX2019008281 appears to include both.
Q3: How can competitors design around this patent?
A: By developing formulations or methods that fall outside the scope of the claims, such as different excipients, ratios, or processes not covered by the patent.
Q4: Are formulations with similar active ingredients automatically infringing?
A: Not necessarily. Infringement depends on whether the formulation or process falls within the scope of the claims.
Q5: How does the patent landscape in Mexico influence global pharmaceutical strategies?
A: Patents in Mexico often mirror global trends but can vary; companies should coordinate patent rights internationally, especially considering Mexico’s role as a key emerging market.
References
[1] Mexican Institute of Industrial Property (IMPI). Patent database. Accessed 2023.
[2] WIPO Patentscope. Global patent data. Accessed 2023.
[3] World Intellectual Property Organization. "Patents and the Mexican Market," 2022.
[4] Mexican Patent Law, Articles 15-23.
This analysis aims to inform pharmaceutical stakeholders of the current scope, claims, and landscape concerning patent MX2019008281, enabling strategic decision-making regarding R&D, licensing, and patent enforcement in Mexico.
